IL-1抑制剂研发策略及临床应用进展

Advances in strategies and clinical applications of interleukin-1 antagonists

白细胞介素-1(IL-1)是促炎细胞因子,在许多急性和慢性炎症性疾病中起着重要作用。通过抑制IL-1活性可以治疗IL-1介导的炎症性疾病。IL-1抑制剂的研发策略有阻断或拮抗IL-1受体和中和IL-1策略等。IL-1抑制剂临床上可用于治疗自身炎症性疾病、关节炎、痛风、卒中、糖尿病及其并发症、肿瘤等疾病,其临床安全性主要关注增加机体感染风险和对造血系统特别是中性粒细胞的影响。IL-1拮抗剂的研发将使更多的炎症相关疾病患者从中获益。

Interleukin-1（IL-1） is an active pro-inflammatory cytokine that plays an important role in the disease related to chronic and acute inflammation. By specifically blocking IL-1,a broad spectrum of inflammatory diseases mediated by IL-1 could be treated. Therapeutic strategies for IL-1 blockade contain blocking IL-1 receptor and neutralizing IL-1 strategies,which can treat autoinflammatory diseases,arthritis,gout,stroke,diabetes and its complications,cancer,and so on. Clinical safety issues with IL-1 blockade contain host defense against infection and effects of IL-1 on haematopoiesis,especially on neutrophil. In short,more and more patients with inflammatory diseases mediated by IL-1 would be benefited from the development of IL-1 antagonists.